secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001140361-25-042118
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin reports Q3 net loss of $0.13/sh; cash $11.5M; NAVIGATE data submitted to FDA
--------------------------------------------------------------------------------

- Net loss of $8.2M ($0.13/share) vs $11.2M ($0.18/share) in Q3 2024; R&D spend down to $2.6M as NAVIGATE trial ended.
- Cash and equivalents $11.5M at Sep 30; plus $10M line of credit from chairman; runway through June 2026.
- New 18-month NAVIGATE biomarker data showed belapectin reduced portal hypertension risk categories vs placebo.
- FDA data package submitted for belapectin in MASH cirrhosis; agency feedback expected by year-end 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125042118/0001140361-25-042118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125042118/ny20058903x1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-042118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer